Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Post-Exposure Prophylaxis Phase III Clinical Trial to Evaluate Protective Efficacy of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate (CT-P59) in Contacts of SARS-CoV-2 Infected Patients

Next Previous
Trial Profile

A Post-Exposure Prophylaxis Phase III Clinical Trial to Evaluate Protective Efficacy of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate (CT-P59) in Contacts of SARS-CoV-2 Infected Patients

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regdanvimab (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Celltrion

Most Recent Events

  • 16 Jul 2021 Results presented in a Celltrion Media Release.
  • 16 Jul 2021 According to a Celltrion media release, data presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
  • 12 Oct 2020 According to a Celltrion media release, the company looks forward to continued data generation as this trial proceeds.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top